The CMA investigated and cleared the anticipated acquisition by Integra LifeSciences Holdings Corporation of the Codman Neurosurgery Business.
|Phase 1 date||Action|
|3 August 2017||Decision published|
|6 July 2017||Decision announced|
|26 May to 12 June 2017||Invitation to comment|
|26 May 2017||Launch of merger inquiry|
CMA clearance decision
6 July 2017: The CMA has cleared the anticipated acquisition by Integra LifeSciences Holdings Corporation of the Codman Neurosurgery Business, using the ‘de minimis’ exception. The full text of the decision is available below.
- Full text decision (3.8.17)
Invitation to comment: Now closed
26 May 2017: The Competition and Markets Authority (CMA) is considering whether it is or may be the case that this transaction, if carried into effect, will result in the creation of a relevant merger situation under the merger provisions of the Enterprise Act 2002 and, if so, whether the creation of that situation may be expected to result in a substantial lessening of competition within any market or markets in the United Kingdom for goods or services.
Launch of merger inquiry
26 May 2017: The CMA announced the launch of its merger inquiry by notice to the parties.
- Commencement of initial period of notice (26.5.17)
Please send written representations about any competition or public interest to:
Published: 26 May 2017
Updated: 3 August 2017
Opened: 26 May 2017
Closed: 3 August 2017
- Full text of the decision published.
- Clearance decision announced.
- First published.